B+
Bull case
20%
Probability
Target price
$6.80
+68.7% vs current
KRMD
KORU MedicalANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-22
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.10
+1.7% vs current
B-
Bear case
30%
Probability
Target price
$2.90
-28.0% vs current
AI sentiment snapshot
Latest data as of 2026-07-23
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+82.1
Score
AI commentary
Company-source news is constructive on Q1 growth and reiterated guidance, but the deterministic signal is negative and the stock remains low coverage. Consensus surprise, analyst revisions, post-print price attribution, options, short interest, employee sentiment, and usable social coverage are unavailable; sentiment therefore supports monitoring rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-07-23
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventSecond-quarter 2026 results scheduledHigh impact
KORU announced it will report second-quarter 2026 results on August 5, 2026. The release is a defined near-term information event, but consensus, surprise magnitude, and post-print analyst reaction are unavailable [#PR-EARNINGS-2026-07-15].
2026-12-31catalystExecution against reiterated 2026 outlookHigh impact
Q1 revenue grew 22.1% year over year to $11.8 million, while management reiterated 2026 revenue of $47.5-$50.0 million, 61%-63% gross margin, positive adjusted EBITDA, and positive cash flow. The key test is whether share gains, international prefilled-syringe conversions, and clinical-trial revenue persist [#SEC-8K-2026-05-06].
2027-07-23catalystExpansion beyond core SCIg applicationsHigh impact
KORU submitted a 510(k) application for deferoxamine use of the Freedom Infusion System, and two non-Ig pharmaceutical collaborations advanced to Phase III trials. Regulatory and commercial timing remains uncertain [#SEC-8K-2026-05-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology